caseintelcaseintel
← Back to Dashboard
Litigation Stage Tracker
Early / Monitoring

Risperdal

ClosedFLAT
MDL 2767Pharma
900+
Total Cases

Causation

Risperdal (risperidone) elevates prolactin levels far more than other antipsychotics, stimulating breast tissue growth. Boys and young men prescribed Risperdal developed gynecomastia requiring surgical mastectomy in severe cases. Internal J&J documents revealed the company knew Risperdal caused prolactin elevation at rates significantly higher than reported in labeling. J&J was found to have illegally marketed Risperdal to children and elderly dementia patients, resulting in a $2.2 billion DOJ settlement in 2013. Philadelphia jury verdicts of $2.5M (2015) and $70M (2016) confirmed corporate knowledge and concealment.

Defendants

EntityRoleNote
Janssen PharmaceuticalsManufacturerJ&J subsidiary — marketed and sold Risperdal in the US
Johnson & JohnsonParent CompanyCorporate parent — oversaw Risperdal marketing strategy
Janssen Research & DevelopmentDrug DeveloperConducted clinical trials and managed regulatory submissions

Litigation Timeline

1993
FDA approves Risperdal for schizophrenia in adults
2006
FDA approves Risperdal for pediatric use (autism irritability, bipolar)
2015-2019
Philadelphia bellwether trials — verdicts up to $70M
2020-2023
Settlement programs resolve majority of 900+ cases
2025-2026
Residual cases pending — MDL largely resolved

Intelligence Signals

No signals yet. Signals populate automatically when scrapers run.

Key Facts

Status
active

Geographic Exposure

·E.D. Pa. (MDL 2767, Judge Rufe)
·Philadelphia Court of Common Pleas (major verdict jurisdiction)
·Nationwide — most cases resolved
·California state court proceedings

Eligibility Criteria

  • Male who took Risperdal (risperidone) as a minor or young adult
  • Diagnosed with gynecomastia (abnormal breast tissue growth)
  • Gynecomastia developed during or after Risperdal use
  • Required surgical intervention (mastectomy) for breast tissue removal